Good Radiopharmacy Practices In Magistral (or Inhouse or Smallscale) Produced Radiopharmaceuticals
Journal Title: Nuclear Medicine Seminars - Year 2020, Vol 6, Issue 3
Abstract
Radiopharmaceuticals differ from normal medicines in that they have a short half-life. Due to the rapid decay, they must be prepared shortly before their clinical use and comprehensive quality control of the final product is not possible: sterility testing, for instance, cannot be performed due to time limits. Therefore, the safe and effective preparation and use of radiopharmaceuticals are vital for the protection of the operator and final user patient. The purpose of this review is to provide more detailed and practical guidance to those involved in the small-scale preparation of PET, therapeutic or other radiopharmaceuticals for commercial or distribution purposes.
Authors and Affiliations
Serap Teksöz, Türkan Ertay
Keywords
Related Articles
- EP ID EP691566
- DOI 10.4274/nts.galenos.2020.0021
- Views 113
- Downloads 0
Procedure Guidelines for Lu-177 PSMA Radyoligand Treatment
Prostate-specific membrane antigen (PSMA) is expressed in most prostate cancers and PSMA-directed radioligand therapy (RLT) with Lutetium-177 (Lu-177) PSMA is promising systemic modality, which involves the delivery of t...
Procedure Guideline for Detection of Inflammation with F-18 FDG PET/CT in Cardiac Sarcoidosis
Histologic confirmation of cardiac sarcoidosis (CS) is challenging. When taken into account of either the invasive nature or potential false negativity of the endomyocardial biopsy, imaging methods represent as a major a...
Guideline for the Treatment of Liver Cancer with Y-90 Radiomicrosphere
Yttrium-90 microsphere therapy, which has become more common in recent years, offers an effective and safe radionuclide treatment option in the treatment of primary and metastatic liver tumors. The success of the treatme...
Guideline for Dopaminergic Imaging in Parkinsonian Syndromes
The purpose of this guideline, which is prepared by the neuropsychiatry imaging task group of the Turkey Association of Nuclear Medicine, is to help nuclear medicine physicians in their practice of dopaminergic imaging i...
Renal Toxicity After Radionuclide Therapy
With the introduction of radionuclide therapies, the probability of toxicity has increased in critical organs such as kidney and bone marrow. Although these toxicity rates are relatively low in targeted therapies such as...